arXiv:2512.08029v4 Announce Type: replace Abstract: Clinical decision-making in oncology requires forecasting how disease evolves under treatment, yet most AI systems remain static predictors that ca...
arXiv:2512. 08029v3 Announce Type: replace Abstract: Clinical decision-making in oncology requires predicting dynamic disease evolution, a task current static AI predictors cannot perform.
arXiv:2606. 08305v1 Announce Type: cross Abstract: Externally controlled survival trials are increasingly used when concurrent randomized controls are infeasible, particularly in oncology and rare-disease settings with time-to-event endpoints.
arXiv:2610.02957v1 Announce Type: new Abstract: World models learn state evolution from trajectories, making access to temporal context a central training requirement. Federated learning can use dist...
arXiv:2606. 05797v1 Announce Type: new Abstract: Longitudinal treatment decisions require predicting potential outcomes under future treatment sequences in the presence of time-varying confounding, heterogeneous patient dynamics, and limited domain-specific data.
The paper introduces Observation‑Anchored Selective Assimilation (OASA) for forecasting tumor‑state proxies in post‑treatment glioma patients using serial MRI observations. OASA anchors the patient‑specific state with an intermediate observation and selectively updates it via a tiered rule and voxel‑wise soft gate, outperforming baseline methods in Dice score at certain thresholds. The approach is validated on 120 patient triplets and the code is publicly released.
A causal multi-modal AI model was developed to predict personalized chemosensitivity in breast cancer patients using routine pathology and clinical data. Trained on 9,141 patients from nine countries and validated on 1,994 patients from three countries, the model produced treatment-specific recurrence probabilities with near-perfect calibration and strong prognostic discrimination over 5- and 10-year horizons. It outperformed existing recurrence-score tests and could reduce chemotherapy prescriptions by 30% while maintaining recurrence-free rates, with predictive performance also transferring to non-breast cancers.
arXiv:2607. 13877v1 Announce Type: new Abstract: Brain tumor progression exhibits spatially heterogeneous growth, patient-specific treatment response, and complex interactions with surrounding anatomy, making accurate long-term prediction challenging.
arXiv:2606. 18281v1 Announce Type: cross Abstract: Conditional average treatment effects (CATEs) are central to treatment decision-making in personalized medicine.
arXiv:2608. 08288v1 Announce Type: new Abstract: Estimating counterfactual outcomes over time from longitudinal observational data is central to clinical decision support.
arXiv:2608. 13518v1 Announce Type: new Abstract: Many clinical prediction models treat post-intervention outcomes as a one-step mapping from baseline measurements to a future endpoint.
arXiv:2610.17426v1 Announce Type: cross Abstract: Clinical decision-making is a sequential process of information collection, clinical inference, and forecasting under partial observability, often wi...